Company Profile

Qianjiang Yong'an Pharmaceutical Co., Ltd. was founded in 2001. It is located in the National High‑Tech Industrial Development Zone of Qianjiang City, at the heart of the Jianghan Plain. Covering an area of more than 400,000 square meters with a registered capital of RMB 294,682,500, it is a national high‑tech enterprise with independent intellectual property rights. The Company’s stock was listed on the Shenzhen Stock Exchange on March 5, 2010 (Stock Code: 002365). Endowed with strong technical development capabilities, the Company is recognised as an Innovative Enterprise of Hubei Province and a Model Enterprise for Intellectual Property Development in Hubei Province. Its R&D platforms have been accredited as a Provincial‑level Enterprise Technology Centre and the Hubei Engineering Technology Research Centre for Functional Food Additives. After years of development, the Company has built a business portfolio centred on the production and sale of taurine for food, feed and pharmaceutical applications, supplemented by upstream‑downstream expansion into ethylene oxide, derivative products and healthcare goods.

The self‑developed ethylene‑oxide‑based production process for taurine has obtained a Torch Programme Certificate issued by the Ministry of Science and Technology of the People’s Republic of China. The Company operates a 40,000‑tonne‑per‑annum ethylene oxide plant adopting the ethylene‑based process, with the ethanol‑based technology licensed from SD Company of the United States as an alternative route, which effectively mitigates price fluctuation risks from a single raw material source.

Equipped with a comprehensive quality control system, the Company has obtained certifications including GMP, ISO9001, ISO22000, BRC and FAMI‑QS, as well as the KOSHER certificate issued by OU of the United States and the HALAL certificate granted by the international Islamic authority. Around 80% of its taurine output is exported globally, making the Company a key supplier for world‑renowned manufacturers.

Core products and annual production capacities are listed as follows: Taurine (78,000 MTs), Creatine Monohydrate (12,000 MTs), Sodium Sarcosinate (50,000MTs).

Committed to the optimisation and innovation of proprietary technologies and driven by capital market resources, the Company will further complete its industrial chain. Guided by its mission “Working for Human Health”, it strives to become a world‑class promoter of human wellness.